Immunogenicity Assay Kit detects anti-drug antibodies.September 22, 2009 -
Dip and Read Immunogenicity Assay Kit, designed for use on Octet® platform, helps life science researchers measure immune response to therapeutic drugs during drug development. It includes protocols that work across many drug types, including antibodies, proteins, and peptides. Incorporated biosensors and basic reagents run enzyme-linked bridging assay and direct binding assay for use with human, primate, and other animal serum and plasma samples.
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Original Press release
ForteBio, Inc.
1360 Willow Road, Suite 205
Menlo Park, CA, 94025
USA
ForteBio Launches Dip and Read(TM) Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies
- Extends Menu of Applications Available on Company's Octet® Platform
MENLO PARK, Calif., Sept. 16 / / - ForteBio , Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, announced today that it has launched the new Dip and Read Immunogenicity Assay Kit for rapid detection of anti-drug antibodies (ADA) for use on the company's Octet platform. The new assay kit provides life science researchers with new levels of throughput, speed and flexibility for measuring immune response to a therapeutic drug, an integral part of drug development.
"Traditional methods for anti-drug antibody detection can be time-consuming, insensitive and labor-intensive, and can result in low throughput," said Christopher Silva, ForteBio's vice president of marketing. "ForteBio's new Dip and Read Immunogenicity Assay Kit overcomes these limitations, providing the needed sensitivity, increased drug tolerance and flexibility to detect both high- and low-affinity ADA. It accomplishes this by leveraging the Octet platform's real-time, label-free detection technology to essentially automate the relevant processing steps and eliminate any plate-washing components."
The Dip and Read Immunogenicity Assay Kit's protocols work across many drug types, including antibodies, proteins and peptides. The assay kit provides biosensors and basic reagents to run two different assay configurations - an enzyme-linked bridging assay and a direct binding assay - for use with human, primate and other animal serum and plasma samples.
ForteBio's Octet system is based on the company's proprietary BioLayer Interferometry (BLI) technology, in which optical biosensors measure multiple interactions in parallel, without the use of detection reagents. The platform includes the Octet QK384 system, which enables 384-well detection, 16-channel simultaneous readout with two plate positions, biosensor regeneration and re-racking, and automation capabilities for increased cost-efficiencies and throughput, as well as faster time to results. The Octet instrumentation software has optional FDA 21 CFR part 11 compliance tools required by GLP laboratories.
About ForteBio, Inc.
ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.
|
User comments about this story
publications and protocols using ForteBio for ADA
would like to get more info and protocols on ForteBIo ADA assay . Is it approved by regulators ? how much the machine and reagents cost ? we are in the field of development of ADA assays for recombinant therapeutic products
Thanks Dr. Khare
By Dr. Aruna G. Khare on Nov 29, 2010 01:12
Reply to this comment
|
|
|
|
|
|
| 
